FOXO Technologies Inc. announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO's machine learning models to analyze epigenetic biomarkers; (ii) the Company's expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources. In connection with the new offering, the Company also announced it has formed a collaboration with KR8.ai Inc. ("KR8") and secured an exclusive license to KR8's AI-based software to support the development and commercial launch of the new health and wellness offering.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.297 USD | -5.35% | +8.75% | -7.10% |
28/04 | FOXO Technologies Inc. announced that it has received $0.11 million in funding from LGH Investments, LLC | CI |
24/04 | Sector Update: Tech Stocks Higher Premarket Wednesday | MT |
1st Jan change | Capi. | |
---|---|---|
-7.10% | 30.02L | |
-13.48% | 19TCr | |
+1.53% | 17TCr | |
+3.37% | 16TCr | |
+8.31% | 10TCr | |
+11.19% | 8.21TCr | |
-6.43% | 7.18TCr | |
-18.66% | 5.41TCr | |
-8.68% | 4.33TCr | |
+9.88% | 3.86TCr |
- Stock Market
- Equities
- FOXO Stock
- News FOXO Technologies Inc.
- FOXO Technologies Inc. Unveils Plans for New Direct-To Consumer Offering Combining the Company's Epigenetic Data with the Power of Ai